•Ferrocenyl-substituted cyclohexenone and indazole derivatives as effective antimycobacterial agents.•Displayed the capacity to effectively suppress the formation of biofilms and disrupt pre-formed biofilms.•Indazole derivative 3b showed potential interactions with the target enzyme as revealed by docking studies and validated by enzyme assay.•Demonstrated good ADMET properties, passed Lipinski's filters, and demonstrated good drug-like properties.•The potential of compound 3b as a potential lead molecule that could be further optimized to develop ferrocene incorporating indazole based antimycobacterial agents. In response to the escalating threat of mycobacterial infections, including extensively drug-resistant tuberculosis (XDR) and multidrug-resistant tuberculosis (MDR), we synthesized novel ferrocene incorporating cyclohexenone and indazole derivatives. The compounds were synthesized via multistep reaction approach starting from chalcone precursors and evaluated against Mycobacterium fortuitum. The MIC and MBC values were calculated by following CLSI guidelines, with a focus on their ability to inhibit bacterial growth and disrupt biofilm formation. All the test compounds showed potent in vitro antimycobacterial activity against M. fortuitum. The MIC values range from 3.907 µg/mL to 500 µg/mL, whereas the MBC values range from 15.625 µg/mL to >500 µg/mL. Among the synthesized compounds, compound 3b exhibited potent antimycobacterial activity compared with standard drug Amikacin used to treat multidrug-resistant tuberculosis. 3b demonstrated significant inhibition of bacterial growth and showed the capacity to effectively suppress biofilm formation and disrupt pre-existing biofilms. This molecule also displayed favourable ADMET profile and good oral bioavailability, besides showing potential interactions with the target enzyme as revealed by docking studies and validated by enzyme assay. Collectively, these studies position 3b as a potential lead molecule that could be further optimized to develop ferrocene incorporating indazole based antimycobacterial agents.